Schrödinger (NASDAQ: SDGR) is a scientific software company that develops and applies computational platforms for drug discovery and materials science. Leveraging physics-based simulation and machine learning, the company’s solutions enable researchers to predict molecular properties, design novel compounds and accelerate the development of pharmaceuticals, specialty chemicals and advanced materials. Schrödinger offers both on-premises and cloud-based access to its software suite, empowering customers to scale computational experiments across projects of varying size and complexity.
The company’s flagship software, Maestro, serves as an integrated environment for molecular modeling, visualization and workflow management. Core technologies such as Glide for molecular docking, Jaguar for quantum mechanical calculations and FEP+ for free energy prediction underpin a broad array of structure‐based design applications. In addition to its software licensing business, Schrödinger provides collaborative research and custom services, partnering with biopharmaceutical firms, academic institutions and materials companies to apply its computational engine to specific discovery challenges.
Founded in 1990 by Nobel Laureate Walter Kohn and a team of computational chemists, Schrödinger has expanded from its academic roots into a publicly traded enterprise headquartered in New York City. Over the years, the company has grown through strategic investments in machine learning and the acquisition of complementary technology platforms. Under the leadership of President and Chief Executive Officer Ramy Farid, Schrödinger has established additional research centers and commercial offices across North America, Europe and Asia, fostering close collaborations with global life sciences and chemical industries.
Schrödinger’s global footprint includes major facilities in the United States, United Kingdom, Austria and India, enabling round-the-clock support and innovation. Its client base spans multinational pharmaceutical corporations, emerging biotech startups and leading academic laboratories, all of which rely on Schrödinger’s computational insights to inform experimental design, reduce development timelines and advance products toward commercialization.
